I have seen a few papers where authors explain that one advantage of an N to C peptide synthesis is the possibility of being able to generate C-terminal modified peptides which have potential application in a therapeutic context (see for example Org. Biomol. Chem., 2013, 11, 3786). Is modification of the C-terminus of a peptide that much of a problem and is there still a real need for such a synthetic approach? Are there many hard to synthesise C-terminal modified peptides that are current "hot" pharmaceutical targets or are they more of academic research interest presently?